Anne Wojcicki, co-founder and former CEO of 23andMe, through her nonprofit TTAM Research Institute, outbid Regeneron with a $305 million offer for the genetic testing company’s assets. The agreement, pending bankruptcy court approval, includes commitments to enhanced privacy protections, consumer choice, and data security. This final round followed a previous $256 million bid from Regeneron and aims to uphold 23andMe’s mission of accessible genomic health insights.